TRULICITY Drug Profile

Summary for Tradename: TRULICITY

High Confidence Patents:	24
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for TRULICITY
Recent Clinical Trials:	See clinical trials for TRULICITY

See drug prices for TRULICITY

Recent Clinical Trials for TRULICITY

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Research Grants Council, Hong Kong	PHASE4
The University of Hong Kong	PHASE4
Eli Lilly and Company	Phase 1

See all TRULICITY clinical trials

Pharmacology for TRULICITY

Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists
Established Pharmacologic Class	GLP-1 Receptor Agonist
Chemical Structure	Glucagon-Like Peptide 1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TRULICITY Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TRULICITY Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,232,041	2037-01-31	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,286,134	2037-01-12	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,751,475	2038-03-30	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,814,082	2037-10-20	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,874,688	2037-10-31	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,933,184	2037-09-27	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,953,196	2037-09-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for TRULICITY Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,004,747	2037-02-09	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,071,992	2037-08-11	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,253,102	2038-06-13	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,369,114	2037-05-24	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,383,918	2037-06-07	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,392,357	2036-06-30	Patent claims search
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	10,485,851	2037-06-07	Patent claims search

International Patents for TRULICITY

Country	Patent Number	Estimated Expiration
Canada	3041761
Denmark	4035719
Mexico	2016013863
Japan	WO2018074294
European Patent Office	3687670
Japan	7316793
European Patent Office	3527240

Market Dynamics and Financial Trajectory for the Biologic Drug: TRULICITY

Last updated: February 3, 2026

---

Summary

TRULICITY (dulaglutide), a GLP-1 receptor agonist developed by Eli Lilly and Company, is a leading injectable treatment for type 2 diabetes mellitus (T2DM). Since FDA approval in 2014, TRULICITY has experienced substantial market growth driven by increasing prevalence of T2DM, evolving treatment guidelines favoring GLP-1 agents, and expanding geographic penetration. This report provides an in-depth analysis of TRULICITY's market dynamics, financial performance, competitive positioning, regulatory landscape, and future projections, offering insights critical for stakeholders.

---

1. Market Overview

Global Type 2 Diabetes Market

Parameter	2022 Estimate	Projection (2028)
Global T2DM Prevalence	537 million (WHO)	693 million
Market Size (USD)	$74.0 billion (2022)	$125.6 billion (2028)
CAGR (2022–2028)	8.2%	8.4%

Source: WHO, IQVIA, Research and Markets

Market Drivers

• Increasing prevalence of obesity and sedentary lifestyles.
• Growing adoption of newer therapeutic classes, especially GLP-1 receptor agonists.
• Favorable treatment guidelines emphasizes GLP-1s for glycemic control and cardiovascular risk reduction.
• Influence of payers' formulary preferences favoring innovative biologics.

Key Segments

Segment	2022 Revenue Share	Key Products	CAGR (2022–2028)
GLP-1 Receptor Agonists	38%	TRULICITY, Ozempic, Mounjaro	9.0%
SGLT2 Inhibitors	25%	Farxiga, Invokana	7.8%
Insulins	30%	Lantus, Tresiba	6.5%
Other	7%	DPP-4 inhibitors, others	4.5%

---

2. TRULICITY's Market Position and Sales Trajectory

Sales Milestones

Year	Estimated Global Sales (USD Millions)	Annual Growth (%)
2014	N/A (launch year)	-
2015	$150 million	N/A
2018	$1.2 billion	55% (average CAGR since launch)
2020	$2.5 billion	25%
2022	$3.3 billion	8%
2023 (estimated)	$3.5 billion	6%

Source: Eli Lilly 10-K 2022, IQVIA IMS Data

Factors Influencing Revenue Growth

• Market Penetration: Predominantly in North America and Europe; expanding in Asia-Pacific.
• Patient Adoption: Driven by guidelines supporting GLP-1s for cardiovascular protection.
• Pricing: Premium pricing (~$900–$1,100/month), subject to payer negotiations.
• Formulation & Dosing: Once-weekly injection improves compliance, expanding eligible patient base.

---

3. Competitive Landscape

Major Competitors

Product	Developer	Approval Year	Key Differentiators	Market Share (2022)
Ozempic	Novo Nordisk	2017	Efficacious, established, once-weekly	35%
Mounjaro	Lilly (another GLP-1)	2022	Superior glycemic effects, weight loss	10%
Rybelsus	Novo Nordisk	2019	Oral GLP-1 option	5%
Others	Various	N/A	Emerging therapies, biosimilars	10%

Competitive Advantages of TRULICITY

• Proven efficacy in glycemic control.
• Cardiovascular outcome trial (REWIND) demonstrated CV risk reduction.
• Once-weekly dosing enhances adherence.
• Established manufacturing capacity and global footprint.

---

4. Regulatory Landscape and Approvals

Region	Approval Year	Key Regulatory Notes
US (FDA)	2014	Approved for T2DM; later extended to obesity indications
EU (EMA)	2015	Approved; positive CV outcomes recognized
Japan	2015	Approved, similar indications
China	2018	Approved, expanding access

Upcoming Regulatory Opportunities

• Obesity Market: Label expansion for weight management pending.
• Combination Therapies: Potential approvals for fixed-dose combinations.
• Pediatric Indications: Under consideration.

---

5. Revenue and Cost Structure Analysis

Cost Component	Approximate Percentage of Revenue	Notes
R&D expenses	12–15%	Focus on next-generation GLP-1s and delivery systems
Manufacturing	20–25%	High biotech manufacturing costs
Marketing & Sales	25–30%	Global sales force, promotional activities
Regulatory & Legal	5–8%	Patent protections, compliance
Profit Margin	15–20%	Reflecting premium pricing, scale efficiencies

Note: Data sourced from Eli Lilly 2022 annual reports.

---

6. Future Financial Trajectory and Growth Drivers

Projected Revenue Growth

Year	Estimated Revenue (USD Millions)	Compound Annual Growth Rate (2023–2028)
2023	$3.5 billion	6% to 8%
2024	$3.7 billion
2025	$4.0 billion
2026	$4.3 billion
2027	$4.6 billion
2028	$5.0 billion

Sources: IQVIA, Eli Lilly projections.

Growth Enablers

• Expansion in Emerging Markets: Strategies include local manufacturing and formulary negotiations.
• Indication Expansion: Obesity and cardiovascular indications.
• Pipeline Synergies: Adjunctive therapies in combination with other biologics.
• Digital Health Integration: Remote monitoring and adherence programs.

---

7. Key Challenges and Risks

Risk Factor	Impact	Mitigation Strategy
Pricing Pressures	Reduced margins, payer restrictions	Value-based pricing, demonstrating CV benefits
Competitive Innovations	Potential market share erosion	R&D to sustain efficacy, pipeline expansion
Patent Litigations	Potential generics or biosimilar entry	Robust patent portfolio, legal defenses
Regulatory Changes	Slower approvals or access restrictions	Proactive engagement with regulators
Supply Chain Disruptions	Manufacturing delays	Diversification, strategic reserves

---

8. Comparative Analysis of TRULICITY with Key Competitors

Aspect	TRULICITY	Ozempic	Mounjaro (Tirzepatide)	Rybelsus (Oral)
Dosing Frequency	Weekly	Weekly	Weekly	Daily
Efficacy (HbA1c reduction)	1.0–1.5%	1.0–1.8%	2.0–2.4%	0.9–1.3%
CV Outcome Data	Yes (REWIND)	Yes (Semaglutide CV trial)	Pending	No
Formulation Type	Injectable	Injectable	Injectable	Oral
Cost per Month	~$900–$1,100	~$850–$1,100	~$900–$1,200	~$700–$850

---

9. FAQs

Q1: What is the primary driver behind TRULICITY's market growth?
A1: The main driver is its demonstrated efficacy in glycemic control, cardiovascular benefits, once-weekly dosing, and growing acceptance under updated clinical guidelines.

Q2: How does TRULICITY compare financially to its competitors?
A2: TRULICITY commands premium pricing but faces intense competition primarily from Ozempic and newly approved Mounjaro, which are also capturing significant market share through superior efficacy and broader indications.

Q3: What are the key regulatory milestones for TRULICITY?
A3: Approval in major markets since 2014, with expanded indications such as CV risk reduction. Future approvals aim to include obesity treatment and pediatric indications.

Q4: What future market opportunities exist for TRULICITY?
A4: Expansion into obesity treatment, combination therapies, emerging markets, and data from ongoing trials presenting potential differentiators.

Q5: What risks could hinder TRULICITY’s financial prospects?
A5: Pricing pressures, patent expirations, competitive entries, regulatory hurdles, and supply chain disruptions.

---

10. Key Takeaways

• Robust Growth Trajectory: Expected to reach USD 5 billion+ by 2028, driven by expanding indications and global adoption.
• Market Competition: Intense rivalry with other GLP-1s like Ozempic and Mounjaro necessitates continuous innovation.
• Regulatory and Segment Expansion: Ongoing approvals and indication expansions are crucial for sustained growth.
• Pricing and Market Access: Maintaining premium pricing hinges on demonstrating clear cardiovascular and metabolic benefits.
• Pipeline and Innovation: Focus on combination therapies, oral formulations, and obesity indications will shape future revenues.

---

References

1. Eli Lilly and Company. (2022). Annual Report.
2. World Health Organization (WHO). (2022). Diabetes Fact Sheet.
3. IQVIA IMS Data. (2022). Global Pharmaceutical Market Insights.
4. FDA Official Database. (2014–2023). Drug Approvals.
5. Research and Markets. (2023). Global Diabetes Market Forecast.

---

This comprehensive analysis provides a strategic view of TRULICITY's market dynamics, competitor landscape, and financial outlook, supporting informed decisions for stakeholders.